|
Astra Zeneca
(N=441)
|
Pfizer-BioNTech
(N=513)
|
RR
(95% CI)
|
AD
(95% CI)
|
p-value
|
Pregnancy outcomes |
Pregnancy outcomes |
Pregnancy outcomes |
Pregnancy outcomes |
Pregnancy outcomes |
Pregnancy outcomes |
Preeclampsia after vaccination – n (%)
|
1 (0.2)
|
5 (1.0)
|
4.3 (0.5, 36.65)
|
0.75 (-0.42, 1.92)
|
0.225
|
Diabetes after vaccination – n (%)
|
1 (0.2)
|
5 (1.0)
|
4.3 (0.5, 36.65)
|
0.75 (-0.42, 1.92)
|
0.225
|
Gestational age at birth – weeks
|
38.4±1.6
|
38.6±1.3
|
-
|
0.1 (-0.1, 0.3)
|
0.176
|
Preterm delivery – n (%) |
|
|
|
|
|
< 28 weeks
|
3 (0.7)
|
0 (0.0)
|
-
|
-
|
-
|
< 34 weeks
|
6 (1.4)
|
8 (1.6)
|
1.15 (0.4, 3.28)
|
0.2 (-1.52, 1.92)
|
0.95
|
< 37 weeks
|
28 (6.4)
|
34 (6.6)
|
1.04 (0.64, 1.69)
|
0.28 (-3.07, 3.62)
|
0.9
|
Oligohydramnios
|
12 (2.7)
|
15 (2.9)
|
1.07 (0.51, 2.26)
|
0.19 (-2.11, 2.49)
|
0.95
|
Polyhydramnios
|
14 (3.2)
|
23 (4.5)
|
1.41 (0.74, 2.71)
|
1.31 (-1.33, 3.95)
|
0.381
|
Being monitored at ICU
|
0 (0)
|
2 (0.4)
|
-
|
-
|
-
|
Stillbirth
|
2 (0.5)
|
1 (0.2)
|
-0.26 (-1.2, 0.69)
|
0.43 (0.04, 4.72)
|
0.6
|
Maternal death
|
0 (0.0)
|
0 (0.0)
|
-
|
-
|
.
|
Neonatal outcomes
|
Neonatal outcomes
|
Neonatal outcomes
|
Neonatal outcomes
|
Neonatal outcomes
|
Neonatal outcomes
|
Birth weight – grams
|
3148.3±376.8
|
3132.1±403.5
|
-
|
-16.1 (-65.9, 33.6)
|
0.524
|
Low birth weight (under 2500g) – n (%)
|
11 (2.5)
|
27 (5.3)
|
2.1 (1.05, 4.18)
|
2.75 (0.12, 5.39)
|
0.046
|
Heavy birth weight (over 4000g) – n (%)
|
6 (1.4)
|
10 (2.0)
|
1.42 (0.52, 3.88)
|
0.58 (-1.25, 2.41)
|
0.66
|
Birthweight percentile
|
50.0 [25.0; 75.0]
|
50.0 [25.0; 75.0]
|
-
|
-
|
0.445
|
Birthweight < 10th percentile – n (%)
|
65 (14.7)
|
85 (16.6)
|
1.12 (0.84, 1.51)
|
1.83 (-3, 6.66)
|
0.493
|
NICU – n (%)
|
24 (5.5)
|
23 (4.5)
|
0.82 (0.47, 1.44)
|
-0.96 (-3.95, 2.03)
|
0.594
|
Birth defects – n (%)
|
4 (0.9)
|
4 (0.8)
|
0.86 (0.22, 3.42)
|
-0.13 (-1.42, 1.17)
|
0.95
|